<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND &amp; AIMS: Effective and selective treatment options are needed for patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The CD24 mucin-like <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> is overexpressed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRCs</z:e>; monoclonal antibodies (mAbs) against CD24 inhibit <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell growth in vitro and in vivo </plain></SENT>
<SENT sid="2" pm="."><plain>Based on the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific expression of CD24, we investigated the potential of anti-CD24 SWA11 mAb, to deliver a cytotoxic agent into <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We conjugated SWA11 to a Pseudomonas exotoxin derivative (PE38) via an Fc-binding ZZ domain from Staphylococcal protein A (which binds the Fc domain of mouse IgG2a immunoglobulins) to generate the immunotoxin SWA11-ZZ-PE38; IgG-ZZ-PE38 was used as control </plain></SENT>
<SENT sid="4" pm="."><plain>Human HT-29 and COLO320 (CD24-positive) and HCT116 (CD24-negative) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines were assayed for immunotoxin binding, cytotoxicity, viability, and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Toxicity and antitumor efficacy were tested in mice </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The immunotoxin preserved the affinity and specificity of SWA11, bound and selectively killed CD24-expressing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells via <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>IC(50) values ranged from 20 to 50 ng/mL-several orders of magnitude lower than that of the mAb alone </plain></SENT>
<SENT sid="8" pm="."><plain>The immunotoxins were not toxic to mice at the maximum dose of 0.75 mg/kg </plain></SENT>
<SENT sid="9" pm="."><plain>Growth of HT-29 xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> was significantly reduced in mice given SWA11-ZZ-PE38 (by 78%) compared to untreated mice </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Anti-CD24 SWA11 mAb can deliver a PE exotoxin derivative to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells and cause them to undergo <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, without toxicity to <z:mpath ids='MPATH_458'>normal</z:mpath> tissues </plain></SENT>
<SENT sid="11" pm="."><plain>This immunotoxin might be developed as a therapeutic treatment for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>